The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
If the government feels that the industry is not complying with the uniform code, it will consider making it a statutory code
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
The investment will accelerate the overall Sarclisa development program
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
Subscribe To Our Newsletter & Stay Updated
